Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Anavex Life Sciences Corp. (AVXL : NSDQ)

• Company Description    ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. Number of Employees: 42

• Price / Volume Information    Yesterday's Closing Price: $8.62 Daily Weekly Monthly 20 Day Moving Average: 1,372,583 shares Shares Outstanding: 85.89 (millions) Market Capitalization: $740.41 (millions) Beta: 0.83 52 Week High: $14.44 52 Week Low: $5.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.12% -5.68% 12 Week -22.76% -26.81% Year To Date -19.74% -29.06%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 630 5TH AVENUE 20TH FLOOR - NEW YORK,NY 10111 USA ph: 844-689-3939 fax: - ir@anavex.com http://www.anavex.com

• General Corporate Information    Officers Christopher Missling - Chief Executive Officer;Director; President and Se Jiong Ma - Chairman and Director Sandra Boenisch - Principal Financial Officer and Treasurer Athanasios Skarpelos - Director Claus van der Velden - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 032797300 SIC: 2836 Fiscal Year Fiscal Year End: September Last Reported Quarter: 06/01/25 Next Expected EPS Date: 12/22/25 Share - Related Items Shares Outstanding: 85.89 Most Recent Split Date: 10.00 (0.25:1) Beta: 0.83 Market Capitalization: $740.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/22/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.09 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -14.29% vs. Previous Quarter: -23.08% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -45.67 03/31/25 - -40.93 ROA 09/30/25 - - 06/30/25 - -40.21 03/31/25 - -36.38 Current Ratio 09/30/25 - - 06/30/25 - 8.93 03/31/25 - 6.74 Quick Ratio 09/30/25 - - 06/30/25 - 8.93 03/31/25 - 6.74 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 1.06 03/31/25 - 1.17 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©